A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker’s multi antigen recognizing (“MAR”)-T cell technology (formerly known as multi-tumor associated antigen-specific T cells, or multiTAA) is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. This approach selectively expands natural tumor-specific T cells from a patient’s/donor’s blood that are capable of recognizing a broad range of tumor associated antigens, or TAAs. Unlike other T cell therapies, MAR-T cells are able to recognize hundreds of different epitopes within up to six tumor-specific antigens to produce broad spectrum anti-tumor activity.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 4.7M | 6.6M | - | - | - | - |
| Net Income | -14M | -11M | -8.2M | -30M | -42M | -29M |
| EPS | $-1.17 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-6.10 |
| Free Cash Flow | 0 | -11M | -16M | -27M | -29M | -23M |
| ROIC | -54.0% | -57.8% | -58.6% | -79.8% | -95.2% | -83.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.19 | 0.22 | 0.76 | 0.55 | 0.67 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -15M | -11M | -15M | -20M | -39M | -29M |
| Operating Margin | -316.7% | -168.7% | - | - | - | - |
| ROE | -77.8% | -65.8% | -58.6% | -152.7% | -95.2% | -105.0% |
| Shares Outstanding | 17M | 9M | 9M | 8M | 8M | 5M |
Marker Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Marker Therapeutics, Inc. (MRKR) has a 5-year average return on invested capital (ROIC) of -75.0%. This is below average and may indicate limited pricing power.
Marker Therapeutics, Inc. (MRKR) has a market capitalization of $27M. It is classified as a small-cap stock.
Marker Therapeutics, Inc. (MRKR) does not currently pay a regular dividend.
Marker Therapeutics, Inc. (MRKR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Marker Therapeutics, Inc. (MRKR) reported annual revenue of $7 million in its most recent fiscal year, based on SEC EDGAR filings.
Marker Therapeutics, Inc. (MRKR) has a net profit margin of -162.8%. The company is currently unprofitable.
Marker Therapeutics, Inc. (MRKR) generated $-11 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Marker Therapeutics, Inc. (MRKR) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
Marker Therapeutics, Inc. (MRKR) reported earnings per share (EPS) of $-1.19 in its most recent fiscal year.
Marker Therapeutics, Inc. (MRKR) has a return on equity (ROE) of -65.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Marker Therapeutics, Inc. (MRKR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Marker Therapeutics, Inc. (MRKR) has a book value per share of $2.06, based on its most recent annual SEC filing.